Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms
We provide novel data on the efficacy of putative and established therapies in patient-derived GEP-NEN primary cultures. Our standardized platform for personalized drug screening and risk assessment in GEP-NEN primary cultures enables prediction of individual tumor treatment response in this orphan disease.
Authors
- Umberto Macciò (ORCID: https://orcid.org/0000-0003-3253-3787)
- F. Beuschlein
- Ralph Fritsch (ORCID: https://orcid.org/0000-0001-9639-3213)
- Martín Reincke (ORCID: https://orcid.org/0000-0002-9817-9875)
- Diana Lindsey Vetter
- José Oberholzer (ORCID: https://orcid.org/0000-0002-1069-2501)
- Constanze Hantel (ORCID: https://orcid.org/0009-0000-8906-2563)
- Katharina Wang (ORCID: https://orcid.org/0000-0002-7795-1395)
- Karel Pacák (ORCID: https://orcid.org/0000-0002-3541-3767)
- Svenja Nölting (ORCID: https://orcid.org/0000-0002-7064-590X)
- Astrid Reul
- Katharina Schilbach (ORCID: https://orcid.org/0000-0002-8667-0296)
- C Auernhammer
- Lea Peischer
- Maximilian Hungbauer
- Kathrin Zitzmann (ORCID: https://orcid.org/0009-0001-2341-3161)
- Julian Maurer
- Julia Hamati
- Elena Kuzmenko
- Edlira Luca
- Ashley B Grossman
Institutions
- University of Zurich (CH)
- The Royal Free Hospital (GB)
- Endocrine Society (US)
- LMU Klinikum (DE)
- University of Oxford (GB)
- European Neuroendocrine Tumor Society (DE)
- University Hospital of Zurich (CH)
- University College London (GB)
- Palacký University Olomouc (CZ)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1210/clinem/dgaf705
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00